Indivior adds Australia for Sublocade regulatory list

Indivior has applied to Australian regulators for its Sublocade monthly treatment injection for opioid dependence.

The Slough-based company filed a regulatory submission with Australia's Therapeutic Goods Administration for the injectable treatment.

"Illicit drug use is a serious public health issue in Australia," said chief executive Shaun Thaxter. "In 2016, the country saw the highest number of drug deaths in the past twenty years, with illicit opioid use alone contributing to more than a thousand deaths.

"As a company, our vision is that all patients around the world have access to evidence-based treatment for the chronic and co-occurring disorders of addiction. We look forward to working closely with regulatory authorities to help make SUBLOCADE, if approved, available to healthcare providers and patients in Australia."

US regulators approved Sublocade in November and an application to Health Canada in April.